AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Orion Oyj

Board/Management Information May 6, 2020

3232_rns_2020-05-06_f9bd9a0d-2fe0-44bc-bff5-8932d3352a0c.html

Board/Management Information

Open in Viewer

Opens in native device viewer

Disclosure 383331

Orion - Other information disclosed according to the rules of the Exchange

Orion Corporation: Organising meeting of the Board of Directors

ORION CORPORATION STOCK EXCHANGE RELEASE 6 MAY 2020 at 17.10 EEST

Orion Corporation: Organising meeting of the Board of Directors

In its organising meeting, the Board of Directors of Orion Corporation, which was elected today by the Annual General Meeting of the Shareholders, has elected Timo Maasilta as Vice Chairman.

The compositions of the Board committees were decided to be as follows:

Remuneration Committee:

Mikael Silvennoinen, Chairman

Timo Maasilta

Hilpi Rautelin

Audit Committee:

Ari Lehtoranta, Chairman

Kari Jussi Aho

Pia Kalsta

Eija Ronkainen

R&D Committee:

Hilpi Rautelin, Chairman

Kari Jussi Aho

Pia Kalsta

Ari Lehtoranta

Timo Maasilta

Eija Ronkainen

Mikael Silvennoinen

The members to the Nomination Committee were elected on 28 October 2019 as stated in the Stock Exchange Release on the same day.

All members of the Board of Directors have been assessed to be independent of the company and its significant shareholders.

Orion Corporation

Timo Lappalainen

President and CEO
Olli Huotari

SVP, Corporate Functions

Contact person:

Olli Huotari, Senior Vice President, Corporate Functions

Phone +358 50 966 3054

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland

http://www.orion.fi/en

http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

Talk to a Data Expert

Have a question? We'll get back to you promptly.